The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
Alto met its enrollment goal with 83 patients across 13 US clinical sites
Iberdomide has the potential to be the first approved CELMoD agent
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
PiNACLE is a head-to-head study comparing its next-generation CAR T-cell therapy against established therapies liso-cel and axi-cel in patients with relapsed or refractory large B-cell lymphoma
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
Subscribe To Our Newsletter & Stay Updated